Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effectiveness of prophylactic treatment
with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion
protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes
while maintaining disease control in males with hemophilia A or B.